secretagogue

(redirected from secretagogues)
Also found in: Dictionary.

secretagogue

 [se-krēt´ah-gog]
1. causing a flow of secretion.
2. an agent that so acts.

se·cre·ta·gogue

(se-krē'tă-gog), Avoid the misspelling secretogogue.
An agent that promotes secretion; for example, acetylcholine, gastrin, secretin.
[secreta + G. agōgos, drawing forth]

secretagogue

/se·cret·a·gogue/ (se-krēt´ah-gog) stimulating secretion, or an agent that so acts.

secretagogue

(sĭ-krē′tə-gôg′, -gŏg′)
n.
A hormone or another agent that causes or stimulates secretion.

secretagogue

[sikrē′təgog′]
any agent that induces exocrine, endocrine, or paracrine secretion.

se·cre·ta·gogue

, secretogogue (sĕ-krētă-gog, -tŏ-gog)
An agent that promotes secretion (e.g., acetylcholine, gastrin, secretin).
[secreta + G. agōgos, drawing forth]

se·cre·ta·gogue

, secretogogue (sĕ-krētă-gog, -tŏ-gog)
Agent that promotes secretion.
[secreta + G. agōgos, drawing forth]

secretagogue

1. causing a flow of secretion.
2. an agent that stimulates secretion.
References in periodicals archive ?
Insulin secretagogues work by stimulating insulin secretion from the pancreatic beta cells.
The growth hormone production in response to growth hormone secretagogue is suppressed by growth hormone releasing hormone antagonist11.
There are some secretagogue agents currently under investigation by pharmaceutical companies.
These results indicate MFME anti diabetic activity might be a result of insulin secretagogue effect through beta cell physiological pathways.
For individuals who take insulin secretagogues she advised moderate amounts of carbohydrate at each meal and snacks.
Disruption of the cell surface and degranulation may be seen in mast cells stimulated with the secretagogues.
Studies have suggested that ghrelin and other growth hormone secretagogues lowers the peripheral resistance either by its direct action on the vessels and /or by regulating the sympathetic nervous activity.
Insulin secretagogues, such as sulfonylurea agents, are associated with weight gain and hypoglycemia, [alpha]-glucosidase inhibitor is associated with some gastrointestinal side effects.
Researchers compared insulin sensitizers and insulin secretagogues in a study that included more than 25,000 patients with diabetes.
The analysis concentrated on insulin sensitisers and insulin secretagogues - the two groups of drugs commonly used to treat type 2 diabetes.
Some other adverse reactions associated with canagliflozin (Invokana) include hypotension, impairment of renal function, hyperkalemia, hypoglycemia with concomitant use with insulin and insulin secretagogues, hypersensitivity reactions and an increase in low-density lipoproteins (LDLs).
Oral medications such as insulin sensitisers and insulin secretagogues are first- and second-line agents in the type 2 diabetes treatment armamentarium and are relatively inexpensive.

Full browser ?